Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Medicenna Therapeutics Corp (TSE:MDNA)
TSX:MDNA
RESEARCH TOOLSreports
Holding TSE:MDNA?
Track your performance easily
MDNA Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$0.38 - C$2.98
Previous CloseC$2.4
Volume71.63K
Average Volume (3M)56.93K
Market Cap
C$182.01M
Enterprise ValueC$146.38M
Total Cash (Recent Filing)C$35.63M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Nov 07, 2024EPS Estimate
-C$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding76,925,289
10 Day Avg. Volume61,348
30 Day Avg. Volume56,929
Standard Deviation0.39
R-Squared0.02
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)8.03
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-19.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Medicenna Therapeutics Corp News
PremiumCompany Announcements
Medicenna Announces Breakthroughs in Cancer Treatment
PremiumCompany Announcements
Medicenna Reveals Key Immunotherapy Data at SITC
PremiumCompany Announcements
Medicenna Shareholders Show Strong Support at Annual Meeting
PremiumCompany Announcements
Medicenna Unveils Groundbreaking Preclinical Therapy Results
PremiumCompany Announcements
Medicenna Therapeutics Showcases at Global Investment Conference
PremiumCompany Announcements
Medicenna to Unveil New Immunotherapy Data in Paris
PremiumCompany Announcements
Medicenna Appoints Industry Veteran to BoardPremiumCompany Announcements
Medicenna Reports Breakthrough Trial Results and Extended RunwayOptions Prices
Currently, No data available
---
Ownership Overview
14.79% Insiders
0.15% Other Institutional Investors
85.05% Public Companies and
Individual Investors
MDNA FAQ
What was Medicenna Therapeutics Corp’s price range in the past 12 months?
Medicenna Therapeutics Corp lowest stock price was C$0.38 and its highest was C$2.98 in the past 12 months.
What is Medicenna Therapeutics Corp’s market cap?
Currently, no data Available
When is Medicenna Therapeutics Corp’s upcoming earnings report date?
Medicenna Therapeutics Corp’s upcoming earnings report date is Nov 07, 2024 which is 2 days ago.
How were Medicenna Therapeutics Corp’s earnings last quarter?
Medicenna Therapeutics Corp released its earnings results on Aug 01, 2024. The company reported -C$0.05 earnings per share for the quarter, missing the consensus estimate of -C$0.045 by -C$0.005.
Is Medicenna Therapeutics Corp overvalued?
According to Wall Street analysts Medicenna Therapeutics Corp’s price is currently Overvalued.
Does Medicenna Therapeutics Corp pay dividends?
Medicenna Therapeutics Corp does not currently pay dividends.
What is Medicenna Therapeutics Corp’s EPS estimate?
Medicenna Therapeutics Corp’s EPS estimate is -C$0.06.
How many shares outstanding does Medicenna Therapeutics Corp have?
Medicenna Therapeutics Corp has 76,797,780 shares outstanding.
What happened to Medicenna Therapeutics Corp’s price movement after its last earnings report?
Medicenna Therapeutics Corp reported an EPS of -C$0.05 in its last earnings report, missing expectations of -C$0.045. Following the earnings report the stock price went up 7.042%.
Which hedge fund is a major shareholder of Medicenna Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:MDNA
---
Medicenna Therapeutics Corp Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
595.65%
12-Months-Change
Fundamentals
Return on Equity
-105.43%
Trailing 12-Months
Asset Growth
20.54%
Trailing 12-Months
Company Description
Medicenna Therapeutics Corp
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines (IL4-ECs) that specifically target the Interleukin-4 Receptor (IL4R) which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The IL4-ECs have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.
---
MDNA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering MDNA
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+253.89%
reiterated a buy rating 9 months ago
Copying Andre Uddin's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +253.89% per trade.
---